title: Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases.
abstract: We report two cases of cutaneous granuloma induced by anti-TNF-alpha therapy: a 47-year-old man suffering from psoriatic arthritis treated with infliximab and a 56-year-old woman treated with adalimumab for polyarticular juvenile rheumatoid arthritis. The biospies confirmed the diagnosis of a 'sarcoidosis-like' reaction. No systemic involvement was observed. Such cases of noninfectious granulomatous diseases occurring during anti-TNF-alpha therapy are becoming increasingly frequent.
authors.affiliation: Department of Dermatology, Amiens University Medical Centre, South Hospital, Amiens, France. Florie.Dhaille @ orange.fr
authors.forename: F
authors.initials: F
authors.lastname: Dhaille
authors.forename: V
authors.initials: V
authors.lastname: Viseux
authors.forename: A
authors.initials: A
authors.lastname: Caudron
authors.forename: A
authors.initials: A
authors.lastname: Dadban
authors.forename: C
authors.initials: C
authors.lastname: Tribout
authors.forename: P
authors.initials: P
authors.lastname: Boumier
authors.forename: A
authors.initials: A
authors.lastname: Clabaut
authors.forename: C
authors.initials: C
authors.lastname: Lok
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012507:Sarcoidosis / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D012871:Skin Diseases / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept